A
LIVE

Serial Number

97920385

Owner

Acuitas Therapeutics, Inc.

Attorney

Karen Won

First Use Date

Oct 18, 2013

Filing Date

May 4, 2023

Add to watchlist:

No watchlists yet
View on USPTO

A Trademark

Serial Number: 97920385 • Registration: 8274549

A is a trademark filed by Acuitas Therapeutics, Inc. on May 4, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Acuitas Therapeutics, Inc. (4 trademarks)

405-6190 Agronomy Road
Vancouver, B.C. V6T1Z3 , CA

Entity Type: 03

Trademark Details

Filing Date

May 4, 2023

Registration Date

May 26, 2026

First Use Anywhere

October 18, 2013

First Use in Commerce

October 18, 2013

Published for Opposition

August 27, 2024

Goods & Services

Pharmaceutical preparations, namely, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acids, namely, messenger RNA and lipid nanoparticles for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders; pharmaceutical preparations, namely, vaccines for human use for treating cancer, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, genetic disorders, allergy; pharmaceutical preparations for gene silencing, for gene editing, for antibody therapeutics, for protein replacement therapeutics, and for nucleic acid therapeutics, for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders

Regulatory compliance consultancy services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid nanoparticles, nucleic acid, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology

Research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; synthetic chemistry services, namely, design, synthesis, analysis, evaluation, and biophysical characterization of lipids, lipid formulations, and lipid nanoparticles; preclinical study services, namely, conducting scientific feasibility studies, namely, pharmacodynamic and pharmacokinetic studies, scientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathology, immune response characterization studies, and bioanalytical services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, and nucleic acid therapeutics; scientific clinical research services, in the fields of chemical molecular analysis, pharmaceutical product optimization, and conducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for others, namely, vaccines and nucleic acid therapeutics; research and development for others in the fields of new pharmaceuticals, medical therapies, vaccines, gene therapies, drug delivery agents, and nucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; consultancy services in the fields of scientific research and development of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 26, 2026 NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 26, 2026 NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 26, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 26, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 2, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 2, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 8, 2026 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 8, 2026 AITU
ASSIGNED TO EXAMINER
Jan 24, 2026 DOCK
USE AMENDMENT FILED
Oct 17, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Oct 17, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 22, 2025 EXRA
SOU EXTENSION 1 GRANTED
Apr 22, 2025 EX1G
SOU EXTENSION 1 FILED
Apr 22, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 22, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 17, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 17, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 17, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 17, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 17, 2024 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 22, 2024 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 18, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 18, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 18, 2024 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 27, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 27, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 7, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 18, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 18, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 18, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 18, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 18, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
May 12, 2024 GNFN
FINAL REFUSAL E-MAILED
May 12, 2024 GNFR
FINAL REFUSAL WRITTEN
May 12, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 16, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 16, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 26, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 26, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 26, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 26, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 3, 2023 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 2, 2023 NWOS
NEW APPLICATION ENTERED
May 8, 2023 NWAP